Calamos Advisors LLC Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Calamos Advisors LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.0% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 570,448 shares of the company's stock after purchasing an additional 5,694 shares during the quarter. Calamos Advisors LLC's holdings in Johnson & Johnson were worth $94,603,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. WealthTrak Capital Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $29,000. Conquis Financial LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $33,000. Bernard Wealth Management Corp. purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new position in shares of Johnson & Johnson in the fourth quarter worth $38,000. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on JNJ. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Finally, Raymond James Financial lowered their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Trading Up 0.0%

Shares of NYSE JNJ traded up $0.02 during trading on Monday, hitting $156.03. 1,213,585 shares of the company were exchanged, compared to its average volume of 8,032,956. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The company has a fifty day moving average price of $153.68 and a 200-day moving average price of $154.17. The firm has a market capitalization of $375.41 billion, a PE ratio of 17.34, a P/E/G ratio of 2.36 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.33%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.